Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-09-17

Clinical Trial Update: Ibrance Real World Insights

View source ↗

Summary

A real-world evidence study of palbociclib (Ibrance) in breast cancer has completed and posted results as of September 17, 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: Malignant Neoplasm of Breast | Status: COMPLETED | Results posted: 2021-09-17